{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T07:51:34Z","timestamp":1717833094045},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/ftd.0000000000000285","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T11:29:56Z","timestamp":1463052596000},"page":"288-292","source":"Crossref","is-referenced-by-count":5,"title":["Are Tacrolimus Pharmacokinetics Affected by Nephrotic Stage?"],"prefix":"10.1097","volume":"38","author":[{"given":"Mara","family":"Medeiros","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u00fal","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma","family":"Del Moral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Vel\u00e1squez-Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto","family":"Casta\u00f1eda-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herlinda","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Filler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210129","doi-asserted-by":"crossref","first-page":"vi75","DOI":"10.1093\/ndt\/gfg1059","article-title":"Treatment of nephrotic syndrome in children and controlled trials","volume":"18","author":"Filler","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R3-2-20210129","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1046\/j.1523-1755.1999.00778.x","article-title":"A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group","volume":"56","author":"Cattran","year":"1999","journal-title":"Kidney Int"},{"key":"R4-2-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1681\/ASN.V7156","article-title":"A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children","volume":"7","author":"Lieberman","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R5-2-20210129","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/ki.1988.59","article-title":"Cyclosporine A induced remission of relapsing nephrotic syndrome in children","volume":"33","author":"Tejani","year":"1988","journal-title":"Kidney Int"},{"key":"R6-2-20210129","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1053\/j.ajkd.2008.11.033","article-title":"Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial","volume":"53","author":"Choudhry","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R7-2-20210129","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00467-012-2228-3","article-title":"Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome","volume":"27","author":"Wang","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R8-2-20210129","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/ki.2012.238","article-title":"Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome","volume":"82","author":"Gulati","year":"2012","journal-title":"Kidney Int"},{"key":"R9-2-20210129","first-page":"33","article-title":"Tacrolimus in steroid resistant and steroid dependent childhood nephrotic syndrome","volume":"96","author":"Supavekin","year":"2013","journal-title":"J Med Assoc Thai"},{"key":"R10-2-20210129","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/13543784.16.7.1099","article-title":"Tacrolimus in the treatment of idiopathic nephrotic syndrome","volume":"16","author":"Westhoff","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"R11-2-20210129","first-page":"2732","article-title":"Monitoring FK 506 concentrations in plasma and whole blood","volume":"23","author":"Jusko","year":"1991","journal-title":"Transplant Proc"},{"key":"R12-2-20210129","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jps.2600820325","article-title":"Plasma protein binding of tacrolimus in humans","volume":"82","author":"Piekoszewski","year":"1993","journal-title":"J Pharm Sci"},{"key":"R13-2-20210129","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/ndt\/12.8.1668","article-title":"Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants","volume":"12","author":"Filler","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"R14-2-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/pch\/7.8.525","article-title":"The transplanted child: new immunosuppressive agents and the need for pharmacokinetic monitoring","volume":"7","author":"Filler","year":"2002","journal-title":"Paediatr Child Health"},{"key":"R15-2-20210129","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jcmg.2009.01.008","article-title":"Synergistic effect of cardiovascular risk factors on necrotic core in coronary arteries: a report from the global intravascular radiofrequency data analysis registry","volume":"2","author":"Garcia-Garcia","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"R16-2-20210129","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10038-006-0048-7","article-title":"Prediction of systemic exposure to cyclosporine in Japanese pediatric patients","volume":"51","author":"Sakaeda","year":"2006","journal-title":"J Hum Genet"},{"key":"R17-2-20210129","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00467-006-0300-6","article-title":"Decreased cyclosporine exposure during the remission of nephrotic syndrome","volume":"22","author":"Medeiros","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R18-2-20210129","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1139\/Y07-025","article-title":"Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats","volume":"85","author":"Medeiros","year":"2007","journal-title":"Can J Physiol Pharmacol"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.6061\/clinics\/2012(10)12","article-title":"Pharmacokinetics of cyclosporin\u2013a microemulsion in children with idiopathic nephrotic syndrome","volume":"67","author":"Henriques Ldos","year":"2012","journal-title":"Clinics (Sao Paulo)"},{"key":"R20-2-20210129","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.clpt.2003.09.001","article-title":"Implication of cholesterol in cyclosporine pharmacodynamics in minimal change nephrotic syndrome","volume":"74","author":"Hirano","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R21-2-20210129","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00467-009-1264-0","article-title":"Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome","volume":"24","author":"Hamasaki","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R22-2-20210129","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/MAJ.0b013e31824ce676","article-title":"Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: a prospective, multicenter clinical trial","volume":"345","author":"Chen","year":"2013","journal-title":"Am J Med Sci"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T01:50:48Z","timestamp":1655862648000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201606000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000285","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}